BB Biotech AG publishes its 2020 annual report
For further information:
Investor Relations Bellevue Asset Management AG, Seestrasse 16, 8700 K?snacht, Switzerland, tel. +41 44 267 67 00 Dr. Silvia Siegfried-Schanz, email@example.com Maria-Grazia Iten-Alderuccio, firstname.lastname@example.org Claude Mikkelsen, email@example.com
Media Relations Bellevue Asset Management AG, Seestrasse 16, 8700 K?snacht, Switzerland, tel. +41 44 267 67 00 Tanja Chicherio, firstname.lastname@example.org
Company profile BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe. BB Biotech is one of the leading investors in this sector. BB Biotech builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.
19.02.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.deLanguage: English Company: BB BIOTECH AG Schwertstrasse 6 8200 Schaffhausen
Switzerland Phone: +41 52 624 08 45 E-mail: email@example.com Internet: www.bbbiotech.ch ISIN: CH0038389992 WKN: A0NFN3 Listed: Regulated Market in Frankfurt (Prime Standard); Mailand, SIX EQS News ID: 1169464 ? End of News DGAP News Service